Try
PRECIGEN, INC.
PGENUnited States
46 filed reports · 582 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
46 reports · Sep 2015 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 32 | 6,472 | Sep 2015 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 11 | 6,135 | Dec 2015 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 2 | 2 | Dec 2023 to Dec 2024 |
| Quarterly · 10-Q/ASEC EDGAR | 1 | 199 | Mar 2018 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 386 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 13, 2026 | 240 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 25, 2026 | 966 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 13, 2025 | 248 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 12, 2025 | 145 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 14, 2025 | 158 | Open |
| FY2024 | 10-K/A | Dec 31, 2024 | Apr 28, 2025 | 1 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 19, 2025 | 460 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 14, 2024 | 176 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 14, 2024 | 159 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 14, 2024 | 165 | Open |
| FY2023 | 10-K/A | Dec 31, 2023 | Apr 29, 2024 | 1 | Open |
Financial data
582 concepts · 12,808 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial562 concepts · 11,899 facts · Dec 2013 to Jul 2026
- Net income loss63 · Dec 2013 to Jun 2026
- Cash and cash equivalents at carrying value62 · Dec 2013 to Jun 2026
- Amortization of intangible assets61 · Dec 2013 to Jun 2026
- Comprehensive income net of tax61 · Dec 2013 to Jun 2026
- Computer hardware and software61 · Dec 2014 to Jun 2026
- Depreciation61 · Dec 2013 to Jun 2026
- Other comprehensive income loss available for sale securities adjustment net of tax61 · Dec 2013 to Jun 2026
- Accretion amortization of discounts and premiums investments60 · Dec 2013 to Jun 2026
- Allocated share based compensation expense60 · Dec 2013 to Jun 2026
- Capital expenditures incurred but not yet paid60 · Dec 2013 to Jun 2026
- Depreciation depletion and amortization60 · Dec 2013 to Jun 2026
- Increase decrease in accounts receivable60 · Dec 2013 to Jun 2026
- Increase decrease in employee related liabilities60 · Dec 2013 to Jun 2026
- Increase decrease in other accrued liabilities60 · Dec 2013 to Jun 2026
- Increase decrease in other operating assets60 · Dec 2013 to Jun 2026
- Increase decrease in other receivables60 · Dec 2013 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets60 · Dec 2013 to Jun 2026
- Net cash provided by used in financing activities60 · Dec 2013 to Jun 2026
- Net cash provided by used in investing activities60 · Dec 2013 to Jun 2026
- Net cash provided by used in operating activities60 · Dec 2013 to Jun 2026
- Payments to acquire property plant and equipment60 · Dec 2013 to Jun 2026
- Share based compensation60 · Dec 2013 to Jun 2026
- Deferred income tax expense benefit59 · Dec 2013 to Dec 2025
- Goodwill (US GAAP)59 · Dec 2013 to Jun 2026
Segment14 concepts · 666 facts · Dec 2017 to Jun 2026
- Revenue185 · Dec 2017 to Jun 2026
- PGEN Therapeutics151 · Dec 2017 to Mar 2024
- Revenue from contracts with customers (excluding tax)83 · Dec 2017 to Dec 2022
- Revenue (excluding assessed tax)47 · Jun 2018 to Sep 2024
- Operating Segments36 · Dec 2022 to Jun 2026
- Exemplar29 · Dec 2020 to Sep 2025
- Goodwill foreign currency translation gain loss28 · Dec 2018 to Dec 2024
- Precigen28 · Jun 2018 to Sep 2019
- Goodwill27 · Dec 2018 to Dec 2024
- Goodwill impairment loss18 · Dec 2019 to Jun 2026
- Labor and related expense13 · Dec 2022 to Jun 2026
- Goodwill transfers12 · Dec 2018 to Dec 2019
- Capital expenditures incurred but not yet paid6 · Dec 2022 to Dec 2024
- Other asset impairment charges3 · Dec 2023 to Dec 2025
Product4 concepts · 165 facts · Dec 2013 to Jun 2026
- Revenue90 · Dec 2016 to Jun 2026
- Cost of goods and services sold (US GAAP)31 · Dec 2016 to Jun 2026
- Collaboration and licensing revenues30 · Dec 2013 to Dec 2017
- Contract with customer liability revenue recognized14 · Dec 2017 to Dec 2024
Geography2 concepts · 78 facts · Sep 2014 to Dec 2024
- Revenue58 · Sep 2014 to Dec 2024
- Property, Plant & Equipment, Net20 · Dec 2014 to Jun 2019
Segments
909 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments29 members · 666 facts
- Exemplar103 · Dec 2019 to Sep 2025
- Biopharmaceuticals84 · Dec 2019 to Mar 2025
- Reportable Segments75 · Dec 2017 to Jun 2026
- Trans Ova74 · Dec 2017 to Mar 2023
- All Other Segments57 · Dec 2017 to Sep 2024
- PGEN Therapeutics36 · Dec 2018 to Dec 2020
- Human Biotherapeutics26 · Dec 2018 to Dec 2020
- Precigen25 · Dec 2017 to Dec 2019
- Methane Bioconversion Platform21 · Dec 2017 to Dec 2019
- Exemplar segment21 · Mar 2020 to Dec 2024
- Acto Bio17 · Dec 2017 to Dec 2020
- Precigen Acto Bio16 · Mar 2019 to Sep 2020
- Trans ova segment16 · Mar 2019 to Mar 2022
- MBP Titan15 · Mar 2019 to Sep 2020
- Reportable Segment Aggregation Before Other Operating15 · Dec 2023 to Dec 2025
- Fine Chemicals12 · Jun 2018 to Sep 2019
- Human biotherapeutics segment9 · Mar 2019 to Dec 2020
- Okanagan8 · Jun 2018 to Sep 2019
- Biopharmaceuticals segment6 · Dec 2020 to Dec 2024
- All other segments5 · Dec 2018 to Dec 2020
- Acto bio4 · Dec 2018 to Dec 2020
- Trans ova segment4 · Dec 2018 to Dec 2021
- Mbptitan segment3 · Mar 2019 to Sep 2019
- Methane bioconversion platform segment3 · Sep 2018 to Sep 2019
- Okanagan segment3 · Jun 2018 to Jun 2019
- Methane bioconversion platform segment2 · Dec 2018 to Dec 2019
- Pgentherapeutics segment2 · Dec 2019 to Dec 2020
- Precigen acto bio segment2 · Mar 2020 to Sep 2020
- Precigen segment2 · Dec 2018 to Dec 2019
Product or servicesrt:ProductOrServiceAxis10 members · 135 facts
- Service38 · Dec 2016 to Jun 2026
- Product33 · Dec 2016 to Jun 2026
- Collaborationandlicensingagreements17 · Dec 2016 to Mar 2020
- Upfront And Milestone Payments14 · Dec 2017 to Dec 2024
- Other12 · Dec 2016 to Sep 2019
- Papzimeos7 · Dec 2023 to Jun 2026
- Exemplar4 · Mar 2025 to Jun 2026
- Product And Service4 · Dec 2023 to Dec 2025
- Product Exemplar3 · Dec 2023 to Dec 2025
- Service Exemplar3 · Dec 2023 to Dec 2025
Statement geographicalus-gaap:StatementGeographicalAxis2 members · 40 facts
- Non Us20 · Sep 2014 to Jun 2018
- Non us20 · Dec 2014 to Jun 2019
Statement geographicalsrt:StatementGeographicalAxis1 member · 38 facts
- Non Us38 · Dec 2016 to Dec 2024
Product or serviceus-gaap:ProductOrServiceAxis2 members · 30 facts
- Research And Development Services15 · Dec 2013 to Dec 2017
- Upfront And Milestone Payments15 · Dec 2013 to Dec 2017
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 4, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.